U.S. Markets close in 3 hrs 46 mins
  • S&P 500

    4,639.58
    +72.58 (+1.59%)
     
  • Dow 30

    34,888.76
    +405.04 (+1.17%)
     
  • Nasdaq

    15,736.82
    +199.13 (+1.28%)
     
  • Russell 2000

    2,227.29
    +28.38 (+1.29%)
     
  • Crude Oil

    67.67
    +1.49 (+2.25%)
     
  • Gold

    1,787.00
    +10.50 (+0.59%)
     
  • Silver

    22.49
    -0.33 (-1.45%)
     
  • EUR/USD

    1.1322
    -0.0017 (-0.1472%)
     
  • 10-Yr Bond

    1.4600
    +0.0170 (+1.18%)
     
  • Vix

    23.83
    -3.36 (-12.36%)
     
  • GBP/USD

    1.3310
    +0.0009 (+0.0666%)
     
  • USD/JPY

    112.8780
    -0.3020 (-0.2668%)
     
  • BTC-USD

    58,532.26
    +1,935.10 (+3.42%)
     
  • CMC Crypto 200

    1,489.77
    +20.69 (+1.41%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Blueprint Medicines: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share were up 678.24% year over year to $11.16, which beat the estimate of $7.72.

Revenue of $745,118,000 rose by 8053.17% year over year, which beat the estimate of $631,570,000.

Looking Ahead

Blueprint Medicines hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Oct 29, 2020

View more earnings on BPMC

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/8kkmicit

Technicals

52-week high: $106.50

Company's 52-week low was at $43.29

Price action over last quarter: Up 42.98%

Company Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.